Abstract:BACKGROUND: Catheter ablation as first-line therapy for ventricular tachycardia (VT) at the time of implantable cardioverter defibrillator (ICD) implantation has not been adopted into clinical guidelines. Also, there is an unmet clinical need to prospectively examine the role of VT ablation in patients with nonischemic cardiomyopathy, an increasingly prevalent population that is referred for advanced therapies globally. METHODS: We conducted an international, multicenter, randomized controlled trial enrolling 180 patients with cardiomyopathy and monomorphic VT with an indication for ICD implantation to assess the role of early, first-line ablation therapy. A total of 121 patients were randomly assigned (1:1) to ablation plus an ICD versus conventional medical therapy plus an ICD. Patients who refused ICD (n=47) were followed in a prospective registry after stand-alone ablation treatment. The primary outcome was a composite end point of VT recurrence, cardiovascular hospitalization, or death. RESULTS: Randomly assigned patients had a mean age of 55 years (interquartile range, 46-64) and left ventricular ejection fraction of 40% (interquartile range, 30%-49%); 81% were male. The underlying heart disease was ischemic cardiomyopathy in 35%, nonischemic cardiomyopathy in 30%, and arrhythmogenic cardiomyopathy in 35%. Ablation was performed a median of 2 days before ICD implantation (interquartile range, 5 days before to 14 days after). At 31 months, the primary outcome occurred in 49.3% of the ablation group and 65.5% in the control group (hazard ratio, 0.58 [95% CI, 0.35-0.96]; P=0.04). The observed difference was driven by a reduction in VT recurrence in the ablation arm (hazard ratio, 0.51 [95%CI, 0.29-0.90]; P=0.02). A statistically significant reduction in both ICD shocks (10.0% versus 24.6%; P=0.03) and antitachycardia pacing (16.2% versus 32.8%; P=0.04) was observed in patients who underwent ablation compared with control. No differences in cardiovascular hospitalization (32.0% versus. 33.7%; hazard ratio, 0.82 [95% CI, 0.43-1.56]; P=0.55) or mortality (8.9% versus 8.8%; hazard ratio, 1.40 [95% CI, 0.38-5.22]; P=0.62]) were observed. Ablation-related complications occurred in 8.3% of patients. CONCLUSIONS: Among patients with cardiomyopathy of varied causes, early catheter ablation performed at the time of ICD implantation significantly reduced the composite primary outcome of VT recurrence, cardiovascular hospitalization, or death. These findings were driven by a reduction in ICD therapies.

Modern physiological approach to inappropriate ICD shocks due to atrial fibrillation with very fast ventricular response. A case report

Analysis of causes of inappropriate discharge of an implantable cardioverter defibrillator in elderly patients

The occurrence characteristics and optimal management of inappropriate shocks in patients with implantable cardioverter defibrillator

Inappropriate Shocks With Subcutaneous Implantable Cardioverter-Defibrillator in a Young Patient: A Case Report

Cause and Treatment of Inappropriate Therapy of Implantable Cardioverter Defibrillators

Retrospective Analysis of the Appropriate and Inappropriate Shock Characteristics in 134 Patients with Implantable Cardioverter-Defibrillator

Conduction system pacing and defibrillation support using a single-chamber defibrillator - A case report

Progress in the Studies of Inappropriate Shocks of Implantable Cardioverter-Defibrillator

Understanding Phantom Shocks in Implantable Cardioverter-Defibrillator Recipients

Inappropriate Therapy and Shock Rates Between the Subcutaneous and Transvenous Implantable Cardiac Defibrillator: A Secondary Analysis of the PRAETORIAN Trial

Implantable Cardioverter Defibrillator Tachycardia Therapies: Past, Present and Future Directions

Ventricular Tachycardia Catheter Ablation: Retrospective Analysis and Prospective Outlooks—A Comprehensive Review

Recent Insights Into Mechanisms and Clinical Approaches to Electrical Storm

Incidence and Causes of Inappropriate Detection and Therapy by Implantable Defibrillators of Cardioversion in Patients with Ventricular Tachyarrhythmia

Appropriate and Inappropriate ICD Shocks in Patients with LVADS: Prevalence, Associated Factors, and Etiologies

First-Line Catheter Ablation of Monomorphic Ventricular Tachycardia in Cardiomyopathy Concurrent With Defibrillator Implantation: The PAUSE-SCD Randomized Trial

An inappropriate pacing threshold increase after repeated electrical storm in a patient with implantable cardioverter defibrillator

Shock Without Wires: A Look at Subcutaneous Implantable Cardioverter-Defibrillator Compared to Transvenous Implantable Cardioverter-Defibrillator for Ventricular Arrhythmias

When Is Less More?

Predicting Malignant Ventricular Arrhythmias Using Real-Time Remote Monitoring

Role of Antiarrhythmic Drugs: Frequent Implantable Cardioverter-Defibrillator Shocks, Risk of Proarrhythmia, and New Drug Therapy